United Therapeutics [UTHR] vs Regencell Bioscience [RGC] Detailed Stock Comparison

United Therapeutics Corporation

NASDAQ
Loading...

Regencell Bioscience Holdings Ltd.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: United Therapeutics Corporation wins in 14 metrics, Regencell Bioscience Holdings Ltd. wins in 1 metrics, with 0 ties. United Therapeutics Corporation appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric United Therapeutics Corporation Regencell Bioscience Holdings Ltd. Better
P/E Ratio (TTM) 20.60 -3,258.62 United Therapeutics Corporation
Price-to-Book Ratio 3.53 2,929.00 United Therapeutics Corporation
Debt-to-Equity Ratio 0.53 11.20 United Therapeutics Corporation
PEG Ratio 0.83 N/A N/A
EV/EBITDA 13.90 -3,921.47 United Therapeutics Corporation
Profit Margin (TTM) 41.94% 0.00% United Therapeutics Corporation
Operating Margin (TTM) 45.23% 0.00% United Therapeutics Corporation
EBITDA Margin (TTM) 45.23% N/A N/A
Return on Equity 19.72% -54.81% United Therapeutics Corporation
Return on Assets (TTM) 12.44% -33.20% United Therapeutics Corporation
Free Cash Flow (TTM) $1.04B $-4.01M United Therapeutics Corporation
1-Year Return 74.63% 3.55% United Therapeutics Corporation
Price-to-Sales Ratio (TTM) 7.91 N/A N/A
Enterprise Value $22.28B $14.48B United Therapeutics Corporation
EV/Revenue Ratio 7.00 N/A N/A
Gross Profit Margin (TTM) 86.91% N/A N/A
Revenue per Share (TTM) $72 $0 United Therapeutics Corporation
Earnings per Share (Diluted) $27.88 $-0.01 United Therapeutics Corporation
Beta (Stock Volatility) 0.75 2.25 United Therapeutics Corporation
Short % of Float 8.58% 1.26% Regencell Bioscience Holdings Ltd.

United Therapeutics Corporation vs Regencell Bioscience Holdings Ltd. Stock Performance Analysis

Loading Price Chart...

UTHR
RGC

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
United Therapeutics Corporation1.74%-6.64%-7.08%5.10%13.90%8.72%
Regencell Bioscience Holdings Ltd.3.09%-4.77%-15.39%-11.30%87.60%12.71%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
United Therapeutics Corporation74.63%156.34%216.46%378.74%788.07%2,079.33%
Regencell Bioscience Holdings Ltd.3.55%3,950.85%8,435.71%8,435.71%8,435.71%8,435.71%

Performance & Financial Health Analysis: United Therapeutics Corporation vs Regencell Bioscience Holdings Ltd.

MetricUTHRRGC
Market Information
Market Cap i$25.11B$14.00B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i464,464105,478
90 Day Avg. Volume i635,891162,743
Last Close$549.47$23.86
52 Week Range$272.12 - $609.35$9.39 - $83.60
% from 52W High-9.83%-71.45%
All-Time High$609.35 (May 06, 2026)$950.00 (May 30, 2025)
% from All-Time High-9.83%-97.49%
Growth Metrics
Quarterly Revenue Growth0.07%N/A
Quarterly Earnings Growth0.21%N/A
Financial Health
Profit Margin (TTM) i0.42%0.00%
Operating Margin (TTM) i0.45%0.00%
Return on Equity (TTM) i0.20%-0.55%
Debt to Equity (MRQ) i0.5311.20
Cash & Liquidity
Book Value per Share (MRQ)$162.60$0.01
Cash per Share (MRQ)$66.63$0.01
Operating Cash Flow (TTM) i$1.56B$-3,113,576
Levered Free Cash Flow (TTM) i$583.20M$-1,507,277
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: United Therapeutics Corporation vs Regencell Bioscience Holdings Ltd.

MetricUTHR (Apr 24, 2026)RGC (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i20.60-3,258.62
Forward P/E i16.87N/A
PEG Ratio i0.83N/A
Price to Sales (TTM) i7.91N/A
Price to Book (MRQ) i3.532,929.00
Market Capitalization
Market Capitalization i$25.11B$14.00B
Enterprise Value i$22.28B$14.48B
Enterprise Value Metrics
Enterprise to Revenue i7.00N/A
Enterprise to EBITDA i13.90-3,921.47
Risk & Other Metrics
Beta i0.752.25
Book Value per Share (MRQ) i$162.60$0.01

Financial Statements Comparison: United Therapeutics Corporation vs Regencell Bioscience Holdings Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricUTHR (2025)RGC (2024)
Revenue/Sales i3.18B0
Cost of Goods Sold i384.40MN/A
COGS % of Revenue i12.1%-
Gross Profit i2.80BN/A
Gross Margin i87.9%-
Research & Development i550.00M1.07M
Operating Income (EBIT) i1.52B-4.74M
Operating Margin i47.7%-
EBITDA i1.84B-3.99M
EBITDA Margin i57.9%-
Pre-Tax Income i1.71B-4.36M
Pre-Tax Income % of Revenue i53.9%-
Income Tax i379.20M0
Income Tax % of Revenue i11.9%-
Net Income (Profit) i1.33B-4.36M
Profit Margin i41.9%-

Balance Sheet & Liquidity Metrics

MetricUTHR (2025)RGC (2024)
Cash & Equivalents i1.56B2.96M
Total Current Assets i3.70B8.11M
Total Current Assets % of Revenue i116.3%-
Total Current Liabilities i560.60M193,578
Total Current Liabilities % of Revenue i17.6%-
Long-Term Debt iN/A25,934
Long-Term Debt % of Revenue i0.0%-
Total Shareholders Equity i7.10B8.22M
Retained Earnings i8.56B-21.62M
Retained Earnings % of Revenue i268.9%-
Property, Plant & Equipment i084,780

Cash Flow Statement Comparison

MetricUTHR (2025)RGC (2024)
Operating Cash Flow i1.44B-3.88M
Operating Cash Flow % of Revenue i45.3%-
Capital Expenditures i-520.50M-5,376
Free Cash Flow i1.04B-4.01M
FCF Margin i32.5%-
Debt Repayment i-500.00MN/A
Common Stock Repurchase i-1.02BN/A

Short Interest & Institutional Ownership Analysis

MetricUTHRRGC
Shares Short i2.84M700,509
Short Ratio i4.405.62
Short % of Float i8.58%1.26%
Shares Outstanding i43.64M494.49M
Float Shares i40.32M43.94M
% Held by Insiders i1.94%88.56%
% Held by Institutions i97.78%0.12%
% Held by Public i0.28%11.32%

Dividend Analysis & Yield Comparison: United Therapeutics Corporation vs Regencell Bioscience Holdings Ltd.

MetricUTHRRGC
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A